Deal facts
- Buyer
- Dolby Medical Home Respiratory Care Limited (Vivisol)
- Target
- Air Liquide Healthcare Limited’s home oxygen services business
- Deal value
- Not disclosed
- Announced
- 11 August 2026
- Status
- Cleared
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- Not stated
Sources
Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic acquisition. The transaction, announced on 11 August 2026, involves the transfer of a significant healthcare asset within the United Kingdom. Vivisol, operating from the UK, is purchasing the specific division of Air Liquide Healthcare Limited, which is also based in the UK. This move represents a consolidation of home respiratory care services under the Vivisol brand. The financial terms of the deal have not been disclosed, and no specific consideration type was reported in the available data. The sector classification for this transaction is healthcare, reflecting the nature of the home oxygen services being transferred from the incumbent provider to the acquiring entity.
The deal structure is defined as a strategic acquisition rather than a management buyout or merger of equals. Both the buyer and the target operate within the same national market, facilitating a straightforward transfer of business operations. The last reported status for the transaction is that a scheme has been proposed. This indicates that the agreement is in the early stages of formalisation. The transaction remains subject to necessary regulatory approvals and internal governance processes before completion. No completion date has been set at this time. The parties are expected to proceed with the required statutory filings to finalise the acquisition of the home oxygen services business.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CMA Phase 1 clearance
Vivisol / Air Liquide (home oxygen services business) merger inquiry
The Competition and Markets Authority (CMA) is seeking views on the anticipated acquisition by Dolby Medical Home Respiratory Care Limited (Vivisol) of Air Liquide Healthcare Limited’s home oxygen services business. Statutory timetable Date Action TBC Deadline for phase 1 decision TBC Launch of merger inquiry 11 August 2026 to late September 2026 Invitation t
UK CMA
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
Dolby Medical Home Respiratory Care Limited (Vivisol)
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive